biotech / news / / New York Post
Otarmeni is designed for people born deaf because of a mutation in a gene called OTOF.
The FDA approved Otarmeni, the first gene therapy for inherited OTOF-related hearing loss.
KEY POINTS
- Regeneron will provide Otarmeni free to all eligible US children and adults.
- Otarmeni restores hearing by delivering a working OTOF gene directly into the cochlea.
- Five of twelve children in the trial achieved essentially normal hearing after gene therapy.
- Otarmeni is the first gene therapy fast-tracked under the FDA's Commissioner’s National Priority Voucher program.
COMPANIES
Summarized by Newsio from New York Post. How we summarize →